0
0
December 15, 2025
EAST LANSING, Mich. — In a landmark development that could end a three-decade drought in new treatments for irregular heart rhythms, researchers at Michigan State University (MSU) have successfully created the first human heart organoids capable of replicating atrial fibrillation (A-fib).
The study, published this week, details how scientists engineered miniature, functional human heart models—complete with immune cells—that mimic the chaotic beating pattern of A-fib. This “disease-in-a-dish” breakthrough offers an unprecedented platform to test drugs for a condition that affects an estimated 60 million people worldwide.
The “Missing Link” in Heart Research
For years, the medical community has struggled to develop effective treatments for arrhythmia because animal models, such as mice, do not perfectly replicate the complex electrophysiology of the human heart. Consequently, no new class of drugs for atrial fibrillation has been introduced in over 30 years.
The MSU team, led by Aitor Aguirre, Associate Professor of Biomedical Engineering, overcame this hurdle by introducing a crucial component previously missing from lab-grown heart models: the immune system.
“We’re now seeing how the heart’s own immune system contributes to both health and disease,” Aguirre said. “This gives us an unprecedented view of how inflammation can drive arrhythmias and how drugs might stop that process.”
How It Works: A Living Laboratory
Organoids are tiny, self-organizing 3D tissue cultures derived from stem cells that mimic the structure and function of actual organs. While heart organoids have been created before, they lacked the complexity to model diseases driven by inflammation.
Colin O’Hern, a physician-scientist student in the Aguirre lab, led the effort to incorporate immune cells, specifically macrophages, into the developing organoids. When the team introduced inflammatory molecules to these enhanced “mini-hearts,” the cells began to beat irregularly, effectively simulating A-fib in a controlled environment.
Crucially, when the researchers treated the chaotic organoids with an anti-inflammatory drug, the heart rhythm partially normalized.
“Our new model allows us to study living human heart tissue directly, something that hasn’t been possible before,” O’Hern explained. “This new model can replicate a condition that is at the core of many people’s medical problems.”
Implications for Public Health
Atrial fibrillation is the most common form of treated heart arrhythmia. It occurs when the upper chambers of the heart (the atria) beat chaotically and out of sync with the lower chambers. This can lead to blood clots, stroke, heart failure, and other heart-related complications.
Current treatments often involve blood thinners or drugs to control heart rate, but these do not address the underlying causes and can carry significant side effects. Ablation procedures, which burn small areas of heart tissue, are invasive and not always permanent.
“For millions of patients, the treatment options have stagnated,” said Dr. Sarah Jenkins, a cardiologist and researcher at the breakdown of cardiovascular disease who was not involved in the study. “Having a human-specific model that links inflammation to arrhythmia is a game-changer. It means we can screen thousands of potential drugs rapidly and safely without putting patients at risk.”
A New Era of Precision Medicine
The potential applications of this technology extend beyond A-fib. The MSU team believes these organoids could be used to screen for cardiotoxicity—damage to the heart muscle—caused by other medications, potentially saving pharmaceutical companies billions of dollars and preventing dangerous drugs from reaching the market.
Furthermore, because the organoids are grown from donated human stem cells, they could theoretically be personalized. In the future, doctors might grow a “mini-heart” from a patient’s own cells to test which arrhythmia medication works best for their specific genetic makeup.
Limitations and Future Directions
While the development is promising, experts caution that organoids are still simplified models. They lack the full body’s systemic interactions, such as signals from the brain or the mechanical pressure of blood pumping through the entire circulatory system.
“These models are incredibly sophisticated, but they are not a full human heart,” noted Dr. Jenkins. “We must validate any findings from these organoids in clinical trials. However, as a first-step screening tool, they are far superior to what we have had in the past.”
The researchers plan to continue refining the complexity of the organoids, hoping to model other congenital heart defects and investigate the role of maternal diabetes on fetal heart development.
“It’s going to enable a lot of medical advances so patients can expect to see accelerated therapeutic developments,” Aguirre added. “Safer drugs and cheaper drugs, too.”
Reference Section
-
Primary Study: Michigan State University. (2025). “Human heart organoids with immune system components replicate atrial fibrillation.” Published in peer-reviewed proceedings linked to the Institute for Quantitative Health Science and Engineering.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
Australian news report on lab-grown heart tissue
This video is relevant as it provides a visual explanation of how scientists are growing tiny heart tissues in the lab to test medications, similar to the research discussed in the article.
